<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               7 DRUG INTERACTIONS<BR>               <BR>                  See also <BR>                        Contraindications (4), Warnings and Precautions (5.5), and <BR>                        Clinical Pharmacology (12.3).<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           VICTRELIS is a strong inhibitor of CYP3A4/5 and is partly metabolized by CYP3A4/5. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 7, 12.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.1	Potential for VICTRELIS to Affect Other Drugs<BR>                     <BR>                        Boceprevir is a strong inhibitor of CYP3A4/5. Drugs metabolized primarily by CYP3A4/5 may have increased exposure when administered with VICTRELIS, which could increase or prolong their therapeutic and adverse effects. Boceprevir does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 in vitro. In addition, boceprevir does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4/5 in vitro.<BR>                        Boceprevir is a potential inhibitor of p-glycoprotein (P-gp) based on in vitro studies. In a drug interaction trial conducted with digoxin, VICTRELIS had limited p-glycoprotein inhibitory potential at clinically relevant concentrations.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.2	Potential for Other Drugs to Affect VICTRELIS<BR>                     <BR>                        Boceprevir is primarily metabolized by aldo-ketoreductase (AKR). In drug interaction trials conducted with AKR inhibitors diflunisal and ibuprofen, boceprevir exposure did not increase to a clinically significant extent. VICTRELIS may be coadministered with AKR inhibitors. <BR>                        Boceprevir is partly metabolized by CYP3A4/5. It is also a substrate for p-glycoprotein. Coadministration of VICTRELIS with drugs that induce or inhibit CYP3A4/5 could decrease or increase exposure to boceprevir.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     7.3	Established and Other Potential Significant Drug Interactions<BR>                     <BR>                        <BR>                           Table 5 provides recommendations based on established or potentially clinically significant drug interactions. VICTRELIS is contraindicated with drugs that are potent inducers of CYP3A4/5 and drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see Contraindications (4)].<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t5"><BR>                           <caption>Table 5 Established and Other Potentially Significant Drug Interactions</caption><BR>                           <col width="30%" align="left" valign="top"/><BR>                           <col width="20%" align="center" valign="top"/><BR>                           <col width="50%" align="left" valign="top"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule" align="center" valign="middle">Concomitant Drug  Class: Drug Name</th><BR>                                 <th styleCode="Rrule" valign="middle">Effect on  Concentration of Boceprevir or Concomitant Drug</th><BR>                                 <th styleCode="Rrule" align="center" valign="middle">Recommendations</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Antiarrhythmics: amiodarone, bepridil, propafenone, quinidine<br/><BR>                                    <br/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; antiarrhythmics<br/><BR>                                    <br/><BR>                                 </td><BR>                                 <td styleCode="Rrule">Coadministration with VICTRELIS has the potential to produce serious and/or life-threatening adverse events and has not been studied. Caution is warranted and therapeutic concentration monitoring of these drugs is recommended if they are used concomitantly with VICTRELIS.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">digoxin<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; digoxin</td><BR>                                 <td styleCode="Rrule">Digoxin concentrations increased when administered with VICTRELIS<content styleCode="italics"> [see<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>. Measure serum digoxin concentrations before initiating VICTRELIS. Continue monitoring digoxin concentrations; consult the digoxin prescribing information for information on titrating the digoxin dose.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Anticoagulant: warfarin</td><BR>                                 <td styleCode="Rrule">&#8593; or &#8595; warfarin</td><BR>                                 <td styleCode="Rrule">Concentrations of warfarin may be altered when co-administered with VICTRELIS. Monitor INR closely.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Antidepressants: trazodone, desipramine</td><BR>                                 <td styleCode="Rrule">&#8593; trazodone<br/>&#8593; desipramine</td><BR>                                 <td styleCode="Rrule">Plasma concentrations of trazodone and desipramine may increase when administered with VICTRELIS, resulting in adverse events such as dizziness, hypotension and syncope. Use with caution and consider a lower dose of trazodone or desipramine.<br/>&#160;</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">escitalopram<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595;escitalopram</td><BR>                                 <td styleCode="Rrule">Exposure of escitalopram was slightly decreased when coadministered with VICTRELIS. Selective serotonin reuptake inhibitors such as escitalopram have a wide therapeutic index, but doses may need to be adjusted when combined with VICTRELIS.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Antifungals: ketoconazole<footnote ID="t5fn1">These combinations have been studied; see <content styleCode="italics"><BR>                                          <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml><BR>                                       </content> for magnitude of interaction.</footnote>, itraconazole, posaconazole, voriconazole</td><BR>                                 <td styleCode="Rrule">&#8593; boceprevir 												<br/><BR>                                    <br/>&#8593; itraconazole<br/>&#8593; ketoconazole<br/>&#8593; posaconazole<br/>&#8593; voriconazole</td><BR>                                 <td styleCode="Rrule">Plasma concentrations of ketoconazole, itraconazole, voriconazole or posaconazole may be increased with VICTRELIS. When coadministration is required, doses of ketoconazole and itraconazole should not exceed 200 mg/day.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Anti-gout: colchicine</td><BR>                                 <td styleCode="Rrule">&#8593; colchicine</td><BR>                                 <td styleCode="Rrule">Significant increases in colchicine levels are expected; fatal colchicine toxicity has been reported with other strong CYP3A4 inhibitors.<br/><BR>                                    <br/>Patients with renal or hepatic impairment should not be given colchicine with VICTRELIS.<br/><BR>                                    <br/>Treatment of gout flares (during treatment with VICTRELIS): 0.6 mg (1 tablet) &#215; 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br/><BR>                                    <br/>Prophylaxis of gout flares (during treatment with VICTRELIS):  If the original regimen was 0.6 mg twice a day, reduce dose to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, reduce the dose to 0.3 mg once every other day.<br/><BR>                                    <br/>Treatment of familial Mediterranean fever (FMF) (during treatment with VICTRELIS): Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Anti-infective: clarithromycin</td><BR>                                 <td styleCode="Rrule">&#8593; clarithromycin</td><BR>                                 <td styleCode="Rrule">Concentrations of clarithromycin may be increased with VICTRELIS; however, no dosage adjustment is necessary for patients with normal renal function.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Antimycobacterial:<br/>rifabutin</td><BR>                                 <td styleCode="Rrule">&#8595; boceprevir<br/>&#8593; rifabutin</td><BR>                                 <td styleCode="Rrule">Increases in rifabutin exposure are anticipated, while exposure of boceprevir may be decreased. Doses have not been established for the 2 drugs when used in combination. Concomitant use is not recommended.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Calcium Channel Blockers, dihydropyridine: felodipine, nifedipine, nicardipine</td><BR>                                 <td styleCode="Rrule">&#8593; dihydropyridine calcium channel blockers</td><BR>                                 <td styleCode="Rrule">Plasma concentrations of dihydropyridine calcium channel blockers may increase when administered with VICTRELIS. Caution is warranted and clinical monitoring is recommended.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Corticosteroid, systemic: dexamethasone</td><BR>                                 <td styleCode="Rrule">&#8595; boceprevir</td><BR>                                 <td styleCode="Rrule">Coadministration of VICTRELIS with CYP3A4/5 inducers may decrease plasma concentrations of boceprevir, which may result in loss of therapeutic effect. Therefore, this combination should be avoided if possible and used with caution if necessary. </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">prednisone<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; prednisone</td><BR>                                 <td styleCode="Rrule">Concentrations of prednisone and its active metabolite, prednisolone, increased when administered with VICTRELIS<content styleCode="italics"> [see<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>. No dose adjustment of prednisone is necessary when co-administered with VICTRELIS. Patients receiving prednisone and VICTRELIS should be monitored appropriately.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Corticosteroid, inhaled: budesonide, fluticasone</td><BR>                                 <td styleCode="Rrule">&#8593; budesonide<br/>&#8593; fluticasone</td><BR>                                 <td styleCode="Rrule">Concomitant use of inhaled budesonide or fluticasone with VICTRELIS may result in increased plasma concentrations of budesonide or fluticasone, resulting in significantly reduced serum cortisol concentrations. Avoid coadministration if possible, particularly for extended durations.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Endothelin Receptor Antagonist: bosentan</td><BR>                                 <td styleCode="Rrule">&#8593; bosentan</td><BR>                                 <td styleCode="Rrule">Concentrations of bosentan may be increased when coadministered with VICTRELIS. Use with caution and monitor closely.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">HIV Integrase Inhibitor:<br/>raltegravir<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule" valign="middle">&#8596; raltegravir</td><BR>                                 <td styleCode="Rrule">No dose adjustment required for VICTRELIS or raltegravir.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">HIV Non-Nucleoside Reverse Transcriptase Inhibitors: efavirenz<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; boceprevir</td><BR>                                 <td styleCode="Rrule">Plasma trough concentrations of boceprevir were decreased when VICTRELIS was coadministered with efavirenz, which may result in loss of therapeutic effect. Avoid combination.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">etravirine<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; etravirine</td><BR>                                 <td styleCode="Rrule">Concentrations of etravirine decreased when coadministered with VICTRELIS. The clinical significance of the reductions in etravirine pharmacokinetic parameters has not been directly assessed.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">HIV Protease Inhibitors: atazanavir/ritonavir<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; atazanavir<br/>&#8595; ritonavir</td><BR>                                 <td styleCode="Rrule">Concomitant administration of boceprevir and atazanavir/ritonavir resulted in reduced steady-state exposures to atazanavir and ritonavir. Coadministration of atazanavir/ritonavir and boceprevir is not recommended.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">darunavir/ritonavir<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; darunavir<br/>&#8595; ritonavir<br/>&#8595; boceprevir</td><BR>                                 <td styleCode="Rrule">Concomitant administration of boceprevir and darunavir/ritonavir resulted in reduced steady-state exposures to boceprevir, darunavir and ritonavir. Coadministration of darunavir/ritonavir and boceprevir is not recommended.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">lopinavir/ritonavir<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; lopinavir<br/>&#8595; ritonavir<br/>&#8595; boceprevir</td><BR>                                 <td styleCode="Rrule">Concomitant administration of boceprevir and lopinavir/ritonavir resulted in reduced steady-state exposures to boceprevir, lopinavir and ritonavir. Coadministration of lopinavir/ritonavir and boceprevir is not recommended.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">ritonavir<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; boceprevir</td><BR>                                 <td styleCode="Rrule">When boceprevir is administered with ritonavir alone, boceprevir concentrations are decreased. </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">HMG-CoA Reductase Inhibitors: atorvastatin<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; atorvastatin</td><BR>                                 <td styleCode="Rrule">Exposure to atorvastatin was increased when administered with VICTRELIS. Use the lowest effective dose of atorvastatin, but do not exceed a daily dose of 40 mg when coadministered with VICTRELIS.<br/>&#160; </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">pravastatin<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; pravastatin</td><BR>                                 <td styleCode="Rrule">Concomitant administration of pravastatin with VICTRELIS increased exposure to pravastatin. Treatment with pravastatin can be initiated at the recommended dose when coadministered with VICTRELIS. Close clinical monitoring is warranted.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Immunosuppressants: cyclosporine<footnoteRef IDREF="t5fn1"/> tacrolimus<footnoteRef IDREF="t5fn1"/> sirolimus</td><BR>                                 <td styleCode="Rrule">&#8593;cyclosporine<br/><BR>                                 </td><BR>                                 <td styleCode="Rrule">Dose adjustments of cyclosporine should be anticipated when administered with VICTRELIS and should be guided by close monitoring of cyclosporine blood concentrations, and frequent assessments of renal function and cyclosporine-related side effects.<br/>&#160;</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">&#8593;tacrolimus<br/><BR>                                 </td><BR>                                 <td styleCode="Rrule">Concomitant administration of VICTRELIS with tacrolimus requires significant dose reduction and prolongation of the dosing interval for tacrolimus, with close monitoring of tacrolimus blood concentrations and frequent assessments of renal function and tacrolimus-related side effects.<br/>&#160;</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule"/><BR>                                 <td styleCode="Rrule">&#8593;sirolimus<br/><BR>                                 </td><BR>                                 <td styleCode="Rrule">Blood concentrations of sirolimus are expected to increase significantly when administered with VICTRELIS. Close monitoring of sirolimus blood levels is recommended. </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Inhaled beta-agonist: salmeterol</td><BR>                                 <td styleCode="Rrule">&#8593; salmeterol</td><BR>                                 <td styleCode="Rrule">Concurrent use of inhaled salmeterol and VICTRELIS is not recommended due to the risk of cardiovascular events associated with salmeterol.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Narcotic Analgesic/Opioid Dependence: methadone<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; R-methadone</td><BR>                                 <td styleCode="Rrule">Plasma concentrations of<content styleCode="italics"> R</content>-methadone decreased when coadministered with VICTRELIS<content styleCode="italics"> [see<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>. The observed changes are not considered clinically relevant. No dose adjustment of methadone or VICTRELIS is recommended. Individual patients may require additional titration of their methadone dosage when VICTRELIS is started or stopped to ensure clinical effect of methadone.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">buprenorphine/naloxone<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; buprenorphine/naloxone</td><BR>                                 <td styleCode="Rrule">Plasma concentrations of buprenorphine and naloxone increased when coadministered with VICTRELIS<content styleCode="italics"> [see<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>. The observed changes are not considered clinically relevant. No dose adjustment of buprenorphine/naloxone or VICTRELIS is recommended.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Oral hormonal contraceptives: drospirenone/ethinyl estradiol<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8593; drospirenone<br/>&#8595; ethinyl estradiol</td><BR>                                 <td styleCode="Rrule">Concentrations of drospirenone increased in the presence of boceprevir. Thus, the use of drospirenone-containing products is contraindicated during treatment with VICTRELIS due to potential for hyperkalemia <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.<br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">norethindrone/ethinyl estradiol<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8595; ethinyl estradiol<br/>&#8596; norethindrone</td><BR>                                 <td styleCode="Rrule">Concentrations of ethinyl estradiol decreased in the presence of boceprevir. Norethindrone C<sub>max</sub> decreased 17% in the presence of boceprevir <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Coadministration of VICTRELIS with a combined oral contraceptive containing ethinyl estradiol and at least 1 mg of norethindrone is not likely to alter the effectiveness of this combined oral contraceptive <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content><BR>                                    <br/><BR>                                    <br/>Patients using estrogens as hormone replacement therapy should be clinically monitored for signs of estrogen deficiency.</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">PDE5 inhibitors: sildenafil, tadalafil, vardenafil</td><BR>                                 <td styleCode="Rrule">&#8593; sildenafil<br/>&#8593; tadalafil<br/>&#8593; vardenafil</td><BR>                                 <td styleCode="Rrule">Increases in PDE5 inhibitor concentrations are expected, and may result in an increase in adverse events, including hypotension, syncope, visual disturbances, and priapism.<br/><BR>                                    <br/>Use of REVATIO<sup>&#174;</sup> (sildenafil) or ADCIRCA<sup>&#174;</sup> (tadalafil) for the treatment of pulmonary arterial hypertension (PAH) is contraindicated with VICTRELIS <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content><BR>                                    <br/><BR>                                    <br/><BR>                                    <content styleCode="underline">Use of PDE5 inhibitors for erectile dysfunction:</content><BR>                                    <br/>Use with caution in combination with VICTRELIS with increased monitoring for PDE5 inhibitor-associated adverse events. Do not exceed the following doses:<br/><BR>                                    <br/>Sildenafil: 25 mg every 48 hours<br/><BR>                                    <br/>Tadalafil: 10 mg every 72 hours<br/><BR>                                    <br/>Vardenafil: 2.5 mg every 24 hours</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">Proton Pump Inhibitor: omeprazole<footnoteRef IDREF="t5fn1"/><BR>                                 </td><BR>                                 <td styleCode="Rrule">&#8596; omeprazole</td><BR>                                 <td styleCode="Rrule">No dose adjustment of omeprazole or VICTRELIS is recommended.</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">Sedative/hypnotics:  alprazolam; IV midazolam</td><BR>                                 <td styleCode="Rrule">&#8593; midazolam<br/>&#8593; alprazolam</td><BR>                                 <td styleCode="Rrule">Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during coadministration of VICTRELIS. A lower dose of IV midazolam or alprazolam should be considered.</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>